Trial · NCT00373204
Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)
NCT00373204, Phase 2, Terminated, Pharmacyclics LLC.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere). Trials, record NCT00373204. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00373204
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)
- NCT number
- NCT00373204
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 50 participants, actual
- Lead sponsor
- Pharmacyclics LLC.
- Conditions
- Lung Cancer
- Interventions
- Motexafin Gadolinium
- First posted
- 2006-09-07
- Last updated
- 2014-07-24
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To assess the complete and partial response rate (CR and PR) in patients with advanced NSCLC when administered motexafin gadolinium (MGd) and docetaxel | up to 12 cycles | The patient population for the primary endpoint is all patients who underwent at least 1 cycle of treatment and at 1 response evaluation. |
| Secondary | To estimate the time of progression | up to 12 cycles | The progression is defined as the time fromfirst does of MGd to first eviedence of progression |
| Secondary | To estimate overall survival | up to 12 cycles | The patient population for this endpoint is all patients who received at least 1 dose of MGd and docetaxel |
| Secondary | To estimate progression-free survival | up to 12 cycles | Progression-free survival is defined as the time from first does of MGd to the earlier of progression |
| Secondary | To estimate duration of response (CR + PR) | Up to 12 cycles | Duration of response (CR +PR) is defined as the time from the fisrt response to the time of disease progression. |
| Secondary | To estimate clinical benefit rate (CR + PR + stable disease [SD]) | up to 12 cycles | The patient population for this endpoint is all patients who underwent at least 2 cycles of treatment and at least 1 response evaluation |
| Secondary | To evaluate the safety and tolerability of the combination of MGd and docetaxel in advanced NSCLC | Up to 12 cycles | All patients who receive at one dose of MGd will be included in the safety summaries and analyses |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00373204
GET https://conductscience.org/api/trials/v1/NCT00373204/registered